Back to Search
Start Over
Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease.
- Source :
-
Psychopharmacology [Psychopharmacology (Berl)] 2008 Jun; Vol. 198 (3), pp. 323-32. Date of Electronic Publication: 2008 Apr 30. - Publication Year :
- 2008
-
Abstract
- Objective: The objective of the study is to investigate the electrocortical and the global cognitive effects of 3 months rivastigmine medication in a group of mild to moderate Alzheimer's disease patients.<br />Materials and Methods: Multichannel EEG and cognitive performances measured with the Mini Mental State Examination in a group of 16 patients with mild to moderate Alzheimer's Disease were collected before and 3 months after the onset of rivastigmine medication.<br />Results: Spectral analysis of the EEG data showed a significant power decrease in the delta and theta frequency bands during rivastigmine medication, i.e., a shift of the power spectrum towards 'normalization'. Three-dimensional low resolution electromagnetic tomography (LORETA) functional imaging localized rivastigmine effects in a network that includes left fronto-parietal regions, posterior cingulate cortex, bilateral parahippocampal regions, and the hippocampus. Moreover, a correlation analysis between differences in the cognitive performances during the two recordings and LORETA-computed intracortical activity showed, in the alpha1 frequency band, better cognitive performance with increased cortical activity in the left insula.<br />Conclusion: The results point to a 'normalization' of the EEG power spectrum due to medication, and the intracortical localization of these effects showed an increase of cortical activity in frontal, parietal, and temporal regions that are well-known to be affected in Alzheimer's disease. The topographic convergence of the present results with the memory network proposed by Vincent et al. (J. Neurophysiol. 96:3517-3531, 2006) leads to the speculation that in our group of patients, rivastigmine specifically activates brain regions that are involved in memory functions, notably a key symptom in this degenerative disease.
- Subjects :
- Aged
Aged, 80 and over
Alzheimer Disease pathology
Alzheimer Disease psychology
Cerebral Cortex pathology
Cholinesterase Inhibitors therapeutic use
Cognition Disorders psychology
Female
Humans
Image Processing, Computer-Assisted
Male
Middle Aged
Neuroprotective Agents therapeutic use
Phenylcarbamates therapeutic use
Psychomotor Performance drug effects
Rivastigmine
Alzheimer Disease drug therapy
Cholinesterase Inhibitors pharmacology
Electroencephalography
Neuroprotective Agents pharmacology
Phenylcarbamates pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 0033-3158
- Volume :
- 198
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Psychopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 18446328
- Full Text :
- https://doi.org/10.1007/s00213-008-1111-1